Oral Sessions
（Day1, Day2, Day3, Day4）
Poster Presentations
（Day1, Day2, Day3, Day4）
Luncheon Seminars
（Day1, Day2, Day3, Day4）
Poster Presentations
- Day 4, May 18（Fri.） Poster
-
4P-14 PDF
Quantitative proteomics analysis of platelets derived from patients with essential thrombocythemia for biomarker discovery
Essential thrombocythemia (ET) is a member of myeloproliferative neoplasms with elevated platelet count of ≥ 450×109/L for > 6 months and with an increased thrombohemorrhagic risk. Major causes of morbidity and mortality in patients with ET are thrombotic complications, with the rate of thrombotic events, predominantly arterial thrombosis, ranging from 2% to 4% patient-years. The presence of mutually exclusive “driver" mutations like JAK2, CALR and MPL helps to elucidate the disease, but there is no curative treatment identified to date. Moreover, ET patients with JAK2-mutation (55%) have higher risk of arterial thrombosis, while extreme thrombocytosis (platelet count ≥ 1000×109/L) or CALR-mutation (25%) reduces the incidence of thrombosis. These further complicate an accurate diagnosis and treatment. Most studies to develop a ET-specific pathognomonic diagnostic test use genomics and transcriptomics, while few proteomics studies focus on the platelet proteome. Since platelets are major players in thrombohemorrphagic events, we used isobaric tags for relative and absolute quantitation (iTRAQTM)-based quantitative proteomics approach to elucidate potential biomarkers from ET or reactive thrombocytosis derived human platelets against healthy donors. We identified proteome changes unique to ET patients' platelets that could aid in predicting for thrombohemorrhagic risk and suggest for potential new targeted treatment approaches.